Skip to content
Politically.com Search all
Menu

2025 · 4th Quarter (Oct 1 - Dec 31)

ALNYLAM PHARMACEUTICALS, INC.

Filed by TODD STRATEGY GROUP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
4th Quarter - Report
Posted
Jan 21, 2026
Income
$60,000.00
Expenses
Not reported
Filing UUID
889d4a0f-38b6-4ae5-ab4c-86d3ef3a5d7f
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Medicare and Medicaid Issues H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.

Literal federal measure citations: H.R.1672, H.R.946

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.